Purpose {#S1}
=======

Cholangiocarcinomas (CCs), including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), are rare, devastating, and highly malignant cancers of bile duct, associated with high mortality due to its aggressive and refractory nature and delayed in diagnosis \[[@ref1],[@ref2]\]. These tumors account for about 10-20% of hepatobiliary cancer-related deaths \[[@ref3]\]. Median survival of patients with locally advanced and unresectable mass is approximately ten months \[[@ref4]\], and five-year survival is less than 10% \[[@ref5]\].

Clinical presentation of ECCs is non-specific, mostly occurring in the elderly population, and patients often present with no specific symptoms. However, some patients might present with rather early symptoms of biliary obstructions or late constitutional symptoms of abdominal mass or discomfort \[[@ref3],[@ref6]\]. Diagnosis of ECCs requires a multidisciplinary approach including clinical laboratory tests, radiography, and endoscopic modalities \[[@ref7]\]. CCs classification is based on anatomical location, macroscopic growth pattern, microscopic characteristics, and cellular origin \[[@ref6]\]. Treatment of choice in CCs is based on patient's health status, biochemical features of tumor, surgical applicability, and stage of the disease \[[@ref7]\]. Surgical resection of the tumor is the first-line therapy with long-term survival in good surgical candidates \[[@ref8]\]; however, only half of the tumors at the time of surgical exploration are resectable \[[@ref9]\]. The initial step in the palliative treatment of patients with unresectable tumors is percutaneous transhepatic biliary decompression, which reduces the symptoms of the patient, such as icterus \[[@ref10]\]. Due to its refractory nature and local recurrence, combined therapy with radiotherapy and chemotherapy has been suggested \[[@ref9]\]. Several treatment protocols using radiotherapy (intraluminal brachytherapy and external beam radiotherapy), combined with systemic chemotherapy and biliary decompression have been recommended in different studies, providing patients with higher survival time and better local control, using intraluminal brachytherapy to deliver a high-dose of radiation to the tumor for enhancement of local control as well as palliation \[[@ref10]\].

The current study was designed to investigate the survival rate of patients with unresectable ECCs in patients receiving multimodality therapeutic protocol (MTP) (biliary drainage + external beam radiotherapy \[EBRT\] + brachytherapy and systemic chemotherapy). Similarly, we aimed to identify the relationship between survival time and associated factors in treatment outcome, including imaging characteristics of the tumor as well as demographic features and staging of the tumor.

Material and methods {#S2}
====================

Study design and participants {#S2_1}
-----------------------------

This study was conducted at our university hospital. All patients with hilar ECCs, in which the tumor was diagnosed as unresectable in imaging findings (magnetic resonance imaging \[MRI\], computed tomography \[CT\] scan, endoscopic ultrasonography), and based on an expert surgeon opinion, between 2012 and 2015, were included into the study. The decision of MTP was made by a multidisciplinary expert team consisting of a radiation oncologist, radiologist, and hepatobiliary surgeon.

Unresectability criteria for patients with ECC \[[@ref11]\] included: 1. Medical comorbidities that restrict the patient's capability to undergo major surgery; 2. Significant underlying liver disease inhibiting curative liver resection according to preoperative imaging; 3. Bilateral tumor extension to secondary biliary tree; 4. Encasement or occlusion of the main portal vein; 5. Lobar atrophy with contralateral portal vein or main hepatic artery involvement; 6. Contralateral tumor extension to secondary biliary tree; 7. Evidence of metastases to N2 level lymph nodes including peripancreatic (head only), paraduodenal, periportal, celiac, superior mesenteric, and/or posterior pancreaticoduodenal lymph nodes; 8. Presence of distant metastases.

All following variables were recorded: demographic variables: age and gender; presence of pruritus: before and after MTP; laboratory tests: total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) before and after MTP; survival time: OS -- overall survival that is defined as survival after the time of diagnosis (month), CS -- survival after catheter placement (month); interval time between diagnosis and catheter placement.

Imaging findings included: involvement of liver parenchyma, involvement of great vessels, regional lymph node invasion, tumor size, and staging: according to Bismuth-Corlette classification \[[@ref12]\], based on the location and extent of the tumor.

Any related complications were also documented such as cholangitis: after MTP based on Charcot's cholangitis triad \[[@ref13]\], gastrointestinal bleeding (GIB), and catheter infection based on catheter tip culture.

Multimodality therapeutic protocol {#S2_2}
----------------------------------

After percutaneous trans-hepatic cholangiography (PTC), an internal-external drainage catheter (F10-12) was placed in the appropriate location under fluoroscopy guidance. After drainage by internal-external biliary catheter, the patients underwent EBRT with high energy linear accelerator (6 or 18 MV photon beams) to the clinical target volume (CTV), defined by primary tumor plus 2 cm margin around the tumor in addition to primary lymph nodes drainage including porta-hepatis, celiac, and pancreaticoduodenal lymph nodes. Planning target volume (PTV) defined as 1-2 cm margin around CTV, and prescribed dose for PTV was 45-50.4 Gy in 25-28 fractions. The patients underwent concurrent chemotherapy by capecitabine (Xeloda) 825 mg/m^2^/bid at the days of radiotherapy. After completion of EBRT (after 7-10 days), in case of bilirubin \< 5 and normal liver function tests, the patients underwent emplacement of 120 cm brachytherapy catheter into internal-external catheter using fluoroscopy guidance, and after passing the catheter from luminal tumoral stricture, the brachytherapy catheter was fixed into the internal-external drainage catheter.

The patients underwent a multi-slice abdominal CT scan with 1 mm thickness before beginning of the treatment. CTV was defined as tumor volume in MRI (before EBRT), with 1-1.5 cm radially and 1-2 cm longitudinally around the catheter, in small number of patients with involvement of right and left hepatic duct at the same time, whose ducts were accessible by catheter, and both hepatic ducts were treated at the same time ([Figure 1](#F1){ref-type="fig"}). The planning was done using a treatment planning software (Flexitron, ELEKTA^®^), and after the planning and dosimetry, the patients were treated by brachytherapy machine (Flexitron, ELEKTA^®^) with iridium-192 (^192^Ir) or cobalt-60 (^60^Co) sources for 21 Gy in 3 fractions in 3 consecutive days (the prescribed dose to CTV was defined as D~90~ = 3 Gy and V~200~ \< 20%). A special attention was paid to the dose-volume histogram of planning with 200% of prescribed dose, which was limited only to the external surface of internal-external drainage catheter. The EQD~2~ (α/β ratio = 10) of brachytherapy was 30 Gy, and when adding the EBRT dose of 45-50 Gy, the total EQD~2~ was 75-80 Gy.

![A patient with cholangiocarcinoma involving both left and right hepatic ducts. **A**) Tumor uptake in positron emission tomography (PET) scan. **B**) Clinical target volume (CTV) and dose coverage in CT planning. **C**) CTV and dose coverage in CT planning. **D**) Bilateral catheter biliary drainage](JCB-12-40411-g001){#F1}

After 4-6 weeks of BT completion, the catheter was removed. Patients who could not tolerate the internal-external catheter for a long time, BT performed before EBRT. In addition, three patients received induction chemotherapy with cisplatin and gemcitabine. There were no treatment breaks recorded in patients, no treatment-related toxicity in our patients that could cause treatment discontinuation, and the overall treatment time was 120 days in all patients. During follow-up, MRI/CT scan and lab data, including liver function test and tumor markers (i.e., CA19-9, CEA) were performed every three months.

Ethics {#S2_3}
------

This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of our institute. After the goals of the study were explained and the patients were assured that their individual data will remain confidential to the research team, all participants signed an informed consent.

Statistical analysis {#S2_4}
--------------------

Data analysis was performed using IBM SPSS 16 for Windows (Chicago, IL, USA), and a *p*-value \< 0.05 was considered statistically significant. Descriptive data (minimum, maximum, range, mean, and standard deviation) of all variables were calculated for all participants. Kolmogorov-Smirnov test was performed to determine the normality distribution of data. Wilcoxon test, a non-parametric test, was applied to assess the association between variables with the abnormal distribution. Kaplan-Meier survival analysis was used to calculate survival. A log-rank test was performed to compare the survival distributions of two samples.

Results {#S3}
=======

A total of 38 eligible patients, with mean SD age = 58.08 (9.80) years (range, 42-74), male = 22 (57.9%), were evaluated. Mean SD of tumor size was 36.66 (12.94) mm (range, 17-70 mm). Regarding the tumor staging, 15 (39.5%) were type IIIA, 5 (13.2%) were type IIIB, 10 (26.3%) were type IV, and 8 (21.2%) were undefined. Two of patients with metastasis were treated with brachytherapy and chemotherapy thereafter.

Of those, 21 (55.3%), 15 (39.5%), and 17 (44.7%) presented with involvement of liver parenchyma, great vessels, and regional lymph nodes, respectively ([Table 1](#T1){ref-type="table"}). Catheter infection occurred in 5 (13.2%) and cholangitis was detected in 2 (5.3%) cases. GIB was also observed only in 1 (2.6%) patient.

###### 

Prognostic factors affecting overall survival (OS) and survival after catheter placement (CS)

  Variables                         *N* (%)   OS          CS                                                                                                        
  --------------------------------- --------- ----------- ------- ---- ------- ------- -------------------------------------------- ------- ------- ------- ------- --------------------------------------------
  Age groups                                                                                                                                                        
                                    \< 50     10 (26.3)   11.90   8    8.11    15.63   0.17                                         8.5     6       5.58    11.40   0.07
                                    50-59     9 (23.6)    17.33   15   14.26   20.40   13.44                                        12      10.42   16.46           
                                    60-69     14 (35.8)   14.07   15   10.97   17.16   10.86                                        9       8.08    13.62           
                                    70-79     5 (13.1)    20.40   20   16.83   23.96   17.40                                        18      14.02   20.77           
  Gender                                                                                                                                                            
                                    Female    16 (42.1)   13.06   13   10.63   15.49   0.03[\*](#TF1-1){ref-type="table-fn"}        9.69    9       7.78    11.59   0.01 [\*](#TF1-1){ref-type="table-fn"}
                                    Male      22 (57.9)   16.59   15   14.05   19.12   13.18                                        10      10.80   15.55           
  Liver parenchyma involvement                                                                                                                                      
                                    Yes       21 (55.3)   12.10   12   9.92    14.26   \< 0.001 [\*](#TF1-1){ref-type="table-fn"}   8.86    9       7.05    10.66   \< 0.001 [\*](#TF1-1){ref-type="table-fn"}
                                    No        17 (44.7)   18.82   17   16.32   21.41   15.24                                        15      12.81   17.66           
  Great vessels involvement                                                                                                                                         
                                    Yes       15 (39.5)   10.60   8    8.12    13.07   \< 0.001 [\*](#TF1-1){ref-type="table-fn"}   7.53    6       5.76    9.30    \< 0.001 [\*](#TF1-1){ref-type="table-fn"}
                                    No        23 (60.5)   18.04   16   15.87   20.21   14.43                                        14      12.33   16.53           
  Bismuth stage                                                                                                                                                     
                                    III       20 (52.6)   17.74   16   14.09   20.01   \< 0.001 [\*](#TF1-1){ref-type="table-fn"}   14.40   14      11.97   16.82   \< 0.001 [\*](#TF1-1){ref-type="table-fn"}
                                    IV        10 (26.3)   7.50    6    5.90    9.09    4.70                                         4       3.92    5.48            
  Regional lymph node involvement                                                                                                                                   
                                    Yes       21 (55.3)   12.76   10   10.15   15.36   0.07                                         9.67    7       7.45    11.88   0.04 [\*](#TF1-1){ref-type="table-fn"}
                                    No        17 (44.7)   18.00   16   15.83   20.16   14.24                                        13      12.08   16.38           
  Tumor size \[mm\]                                                                                                                                                 
                                    \< 25     5 (12.8)    19.80   20   17.23   22.36   0.29                                         17.00   18      13.74   20.25   0.07
                                    ≥ 25      33 (87.2)   14.39   15   12.38   16.40   10.90                                        9       9.17    12.64           

statistically significant, OS -- overall survival, CS -- survival after catheter placement

Mean SD of OS was 15.11 (8.10) months, with median = 15 (95% CI: 13.25-16.69) ([Figure 2](#F2){ref-type="fig"}), and CS was 2-29 months, with mean SD = 11.71 (7.29) (median = 10; 95% CI: 10.05-13.37) ([Figure 2](#F2){ref-type="fig"}).

![Kaplan-Meier graph for (**A**) overall survival (OS), and (**B**) after catheter placement (CS) for all patients](JCB-12-40411-g002){#F2}

The interval time between diagnosis and catheter placement was 1-12 months, with mean SD = 3.39 (2.58). There was no significant relationship between the interval time between diagnosis and catheter placement in OS or CS (*p* = 0.21 and 0.07, respectively).

Pruritus was reported in 35 (92.1%) patients at the time of catheter placement and in follow-up, only 3 (7.9%) cases of pruritus were reported. The difference in the number of patients with pruritus before and after catheter insertion was found to be significant (*p* \< 0.001). However, no patient reported new-onset pruritus after catheter placement.

Our analysis showed a significant decline in serum levels of total bilirubin, AST, ALT, and ALP after catheter placement (*p* \< 0.001 for all variables) ([Table 2](#T2){ref-type="table"}).

###### 

Change of laboratory tests after catheter placement

  Lab test          Catheter placement   *P*-value         
  ----------------- -------------------- ----------------- --------------------------------------------
  Total bilirubin   11.88 (4.12)         3.35 (2.07)       \< 0.001 [\*](#TF2-1){ref-type="table-fn"}
  AST               127.42 (117.69)      84.69 (89.54)     \< 0.001 [\*](#TF2-1){ref-type="table-fn"}
  ALT               127.00 (137.07)      80.58 (86.44)     \< 0.001 [\*](#TF2-1){ref-type="table-fn"}
  ALP               1533.84 (673.42)     582.97 (306.61)   \< 0.001 [\*](#TF2-1){ref-type="table-fn"}

statistically significant, AST -- aspartate aminotransferase, ALT -- alanine aminotransferase, ALP -- alkaline phosphatase

OS and CS did not indicate a significant difference between various age groups (*p* = 0.17 and 0.07, respectively) ([Table 1](#T1){ref-type="table"}). This association, however, was significant in terms of gender, where males were more likely to have higher OS (median = 15 vs. 13 months) and CS (median = 10 vs. 9 months) (*p* = 0.03 and 0.01, respectively) ([Table 1](#T1){ref-type="table"} and [Figure 3](#F3){ref-type="fig"}).

![Kaplan-Meier graph for (**A**) overall survival (OS), and (**B**) after catheter placement (CS) in different genders](JCB-12-40411-g003){#F3}

Further analysis revealed a considerable decrease in OS and CS in patients with an involvement of liver parenchyma, great vessels, regional lymph nodes, and Bismuth type IV ([Table 1](#T1){ref-type="table"}). This correlation, however, was marginally lower for tumor ≥ 25 mm in size regarding CS (*p* = 0.07), but was not significant for OS (*p* = 0.29) ([Table 1](#T1){ref-type="table"}).

Discussion {#S4}
==========

Treatment of choice in CCs, which show a higher survival rate (5-year survival of 10-40%), is a surgical resection with a negative margin that often requires lymphadenectomy and major hepatectomy \[[@ref12],[@ref13]\]. Unfortunately, only approximately 20% of patients are the candidates for radical resection, and the rest of patients benefit from palliative treatments \[[@ref10]\]. Palliative options include surgical, percutaneous, and endoscopic palliations. The aim of palliative therapy is to relieve from obstructive symptoms (pain, jaundice, pruritus, and cholangitis) and quality of life improvement \[[@ref14]\].

In patients with advanced cancers, percutaneous placement of the catheter is the first choice in palliative therapy, with low complications and mortality \[[@ref10]\]. Moreover, radiotherapeutic modalities (EBRT and BT) have been shown to have promising outcomes as a part of palliative therapy \[[@ref15]\]. The addition of radiation to chemotherapy resulted in a significant improvement in 2-year OS (25.8% vs. 20.0%) \[[@ref16]\]. Another therapeutic approach is the combination of radiotherapy and chemotherapy to achieve a higher local and systemic control \[[@ref17]\]. Hence, we defined the MTP as percutaneous intervention + EBRT + brachytherapy + systemic chemotherapy, to be administered in patients with unresectable ECCs.

The median survival after diagnosis (OS) and after catheter placement (CS) was measured as 15 and 10 months, respectively. Complications included: catheter infection, cholangitis, and GIB reported in 13.2%, 5.3%, and 2.6%, respectively. Our total outcomes (survival time and complication rates) were comparable to the following previous studies. Earlier studies, with an almost similar protocol, reported the same survival rates \[[@ref15],[@ref16],[@ref17]\]. Other papers, however, showed higher survival time, but complications were significantly higher, comparing to the current study \[[@ref18],[@ref19]\]. There are several studies that did not use systemic chemotherapy, and their results showed a lower survival time \[[@ref20],[@ref21],[@ref22],[@ref23]\].

In a study by Mahadevan *et al*. \[[@ref18]\], patients were treated with stereotactic body radiotherapy (SBRT) at a median dose of 30 Gy daily in three fractions, along with chemotherapy with gemcitabine, and reported a 17-month survival at the end of study. They reported complications as a duodenal ulcer (5.8%), cholangitis (2.9%), and liver abscess (2.9%). An increased survival rate and lower total complications have been reported, as compared with our study.

Barney *et al*. \[[@ref24]\] used SBRT using a dose of 45-60 Gy every 3 to 5 days, over one week, with a median prescription dose of 55 Gy, and chemotherapy was used before radiotherapy. They eventually reported one-year survival for their patients, in which a case of hepatic failure (10%) and a case of biliary obstruction (10%) were reported. This study has resulted in less survival and more complications, as compared with the current study.

In another study by Foo *et al*. \[[@ref19]\], patients underwent EBTR, BT, and chemotherapy, and a median survival of 12.8 months was reported. In a previous study by Takamura *et al*. \[[@ref15]\], patients underwent EBRT, BT, and stent insertion, with a median survival rate of one-year. Furthermore, Shinohara *et al*. \[[@ref25]\] treated patients with EBRT and BT without using chemotherapy, and described an 11-month survival at the end of study.

Autorino and colleagues \[[@ref26]\] presented 27 patients with unresectable ECC. One group of patients underwent EBRT + concurrent gemcitabine, and the other group was treated with EBRT+ concurrent gemcitabine + intraluminal HDR brachytherapy with 15-20 Gy. Median OS and LC were significantly better in the brachytherapy group.

This discrepancy in survival time among various studies might be due to the following reasons: 1. Patients' inequality in demographic features and comorbidities status; 2. Difference in staging system (Bismuth vs. the American Joint Committee on Cancer -- AJCC); 3. Heterogeneity in patients regarding their tumor stage; 4. Dissimilarity in defining and techniques of performing the MTP in terms of EBRT and brachytherapy dosages, dosage and type of the drug combination in chemotherapy, and period of administration.

Furthermore, the current study revealed a negative impact of the involvement of liver parenchyma, great vessels, regional lymph nodes, and higher tumor staging according to Bismuth classification on survival time in patients who underwent the MTP. No considerable difference, however, was observed in different groups regarding age and tumor size; however, the survival time was significantly higher in males.

Similar prognostic factors have been reported in lymph node metastasis \[[@ref27]\] and tumor stage \[[@ref28]\]. In Wellner's study \[[@ref27]\], adjuvant chemotherapy after surgery did not play a role in patients with prognosis. However, results in terms of perineural involvement, lymph node metastasis, positive surgical margin, and undifferentiated adenocarcinoma were found to be associated with survival. Another study by Vern-Gross \[[@ref29]\] also suggested that local involvement and distant metastasis were effective factors in survival, while additional radiotherapy for post-surgical treatment influenced the improvement of overall survival or cancer-specific survival (CSS) in patients. Fuller *et al*. \[[@ref28]\] reported the following factors to be effective in the survival of patients with ECCs including age, AJCC stages, tumor grade, and usage of surgery or radiotherapy. Murakami *et al*. \[[@ref30]\] also considered adjuvant chemotherapy, positive surgical margin, and lymph node metastases as significant factors in patients' survival.

In addition to the variety of therapeutic approaches, the difference in reported prognostic factors can be due to the varying number of patients in each study and the duration of patients' follow-up.

Limited sample size and lack of control group were the most substantial limitation of the present study. Therefore, further investigations, particularly randomized clinical trials with a large sample size, regarding the efficacy of different chemotherapy regimens and combination with EBRT and brachytherapy, are recommended.

Conclusions {#S5}
===========

The multimodality therapeutic approach in patients with inoperable ECCs could definitely improve their survival time and decrease complications. Survival time is significantly depended on tumor staging, gender, and involvement of liver parenchyma, great vessels, and regional lymph nodes.
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